Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome: A Randomized Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-Loaded Eptifibatide in the Treatment of Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS)
Latest Information Update: 17 Feb 2022
Price :
$35 *
At a glance
- Drugs Eptifibatide (Primary) ; Aspirin; Heparin; Low molecular weight heparins
- Indications Acute coronary syndromes; Myocardial ischaemia
- Focus Biomarker; Therapeutic Use
- Acronyms EARLY-ACS
- Sponsors Merck Sharp & Dohme; Schering-Plough
- 28 Jan 2020 Results of post hoc, subanalysis, in the EARLY ACS, exploring the association between morphine and ischemic events (n=5,438) in patients treated with concomitant clopidogrel, with Patients not treated with clopidogrel (n = 3,462) are used as negative controls,presenting with non-ST-segment elevation acute coronary syndromes (NSTEACS) published in the Journal of the American College of Cardiology
- 09 Nov 2012 Planned number of patients changed from 9500 to 10500 as reported by European Clinical Trials Database record.
- 30 Mar 2009 Results presented at the American College of Cardiology meeting and reported in the New England Journal of Medicine, as reported by Schering-Plough.